Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Clinical trials sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., explained in plain language.
-
Early trial halted for new lymphoma pill
Disease control TerminatedThis early-stage study tested a new oral drug called TQB3909 in adults whose mantle cell lymphoma had returned or stopped responding to other treatments. The main goals were to find a safe dose for future testing and to closely monitor for any side effects. The trial was terminat…
Phase: PHASE1, PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Early-Stage trial halted for advanced bone cancer treatment
Disease control TerminatedThis early-stage trial tested a new two-drug combination for people with advanced bone cancer (osteosarcoma) or other solid tumors that had returned or spread after standard treatments. The goal was to see if the combination could slow cancer growth and was safe. The study was te…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC